Exact Mass: 465.2839

Exact Mass Matches: 465.2839

Found 49 metabolites which its exact mass value is equals to given mass value 465.2839, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

LysoPC(14:1(9Z)/0:0)

(2-{[(2R)-2-hydroxy-3-[(9Z)-tetradec-9-enoyloxy]propyl phosphono]oxy}ethyl)trimethylazanium

C22H44NO7P (465.2855)


LysoPC(14:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(14:1(9Z)), in particular, consists of one chain of myristoleic acid at the C-1 position. The myristoleic acid moiety is derived from milk fats. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(14:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(14:1(9Z)), in particular, consists of one chain of myristoleic acid at the C-1 position. The myristoleic acid moiety is derived from milk fats. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.

   

N-Eicosapentaenoyl Tyrosine

3-(4-hydroxyphenyl)-2-(icosa-5,8,11,14,17-pentaenamido)propanoic acid

C29H39NO4 (465.2879)


N-eicosapentaenoyl tyrosine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Tyrosine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Tyrosine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Tyrosine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   
   

16-Deethylindanomycin

16-Deethylindanomycin

C29H39NO4 (465.2879)


Origin: Microbe, Heterocyclic compounds, Pyrans

   
   

incednam|incednine aglycon

incednam|incednine aglycon

C29H39NO4 (465.2879)


   

PE(17:1(9Z)/0:0)

PE(17:1(9Z)/0:0)

C22H44NO7P (465.2855)


   

PC(14:1/0:0)

3,5,9-Trioxa-4-phosphatricos-18-en-1-aminium, 4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, [R-(Z)]-

C22H44NO7P (465.2855)


   

PC(14:2l8,8/0:0)[U]

3,5,9-Trioxa-4-phosphatricosan-1-aminium, 17,17-difluoro-4,7-dihydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide

C22H44NO7P (465.2855)


   

PE(17:1/0:0)

1-(9Z-heptadecenoyl)-sn-glycero-3-phosphoethanolamine

C22H44NO7P (465.2855)


   

LPC(14:1)

1-Myristoleoyl-glycero-3-phosphocholine

C22H44NO7P (465.2855)


   

LPC 14:1

1-(9Z-tetradecenoyl)-sn-glycero-3-phosphocholine

C22H44NO7P (465.2855)


   

LPE 17:1

1-(9Z-heptadecenoyl)-sn-glycero-3-phosphoethanolamine

C22H44NO7P (465.2855)


   

Cytochalasin J1

Cytochalasin J1

C29H39NO4 (465.2879)


   

Cytochalasin H2

Cytochalasin H2

C29H39NO4 (465.2879)


   

1-Azoniabicyclo(2.2.2)octane, 1-(2-(4-fluorophenyl)ethyl)-3-((2S)-1-oxo-2-phenyl-2-(1-piperidinyl)propoxy)-, (3R)-

1-Azoniabicyclo(2.2.2)octane, 1-(2-(4-fluorophenyl)ethyl)-3-((2S)-1-oxo-2-phenyl-2-(1-piperidinyl)propoxy)-, (3R)-

C29H38FN2O2+ (465.2917)


   

N-Eicosapentaenoyl Tyrosine

N-Eicosapentaenoyl Tyrosine

C29H39NO4 (465.2879)


   

1-(1-Adamantyl)-3-[8-[[1-(2-furanylmethyl)-5-tetrazolyl]methyl]-8-azabicyclo[3.2.1]octan-3-yl]urea

1-(1-Adamantyl)-3-[8-[[1-(2-furanylmethyl)-5-tetrazolyl]methyl]-8-azabicyclo[3.2.1]octan-3-yl]urea

C25H35N7O2 (465.2852)


   

1-(10z-Heptadecenoyl)-sn-glycero-3-phosphoethanolamine

1-(10z-Heptadecenoyl)-sn-glycero-3-phosphoethanolamine

C22H44NO7P (465.2855)


   

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-heptadec-10-enoate

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-heptadec-10-enoate

C22H44NO7P (465.2855)


   

[2-hydroxy-3-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-hydroxy-3-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C22H44NO7P (465.2855)


   

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-heptadec-9-enoate

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-heptadec-9-enoate

C22H44NO7P (465.2855)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] acetate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] acetate

C22H44NO7P (465.2855)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] butanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] butanoate

C22H44NO7P (465.2855)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] propanoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] propanoate

C22H44NO7P (465.2855)


   
   
   

1-(9Z-tetradecenoyl)-sn-glycero-3-phosphocholine

1-(9Z-tetradecenoyl)-sn-glycero-3-phosphocholine

C22H44NO7P (465.2855)


   

1-(9Z-heptadecenoyl)-sn-glycero-3-phosphoethanolamine

1-(9Z-heptadecenoyl)-sn-glycero-3-phosphoethanolamine

C22H44NO7P (465.2855)


   

lysophosphatidylcholine 14:1

lysophosphatidylcholine 14:1

C22H44NO7P (465.2855)


A lysophosphatidylcholine in which the remaining acyl group contains 14 carbons and 1 double bond. If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.

   

lysophosphatidylcholine 14:1(9Z)/0:0

lysophosphatidylcholine 14:1(9Z)/0:0

C22H44NO7P (465.2855)


A lysophosphatidylcholine 14:1 in which the remaining acyl group is (9Z)-tetradecenoyl.

   

PC(14:1)

PC(8:1(1)_6:0)

C22H44NO7P (465.2855)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

NA-Tyr 20:5(5Z,8Z,11Z,14Z,17Z)

NA-Tyr 20:5(5Z,8Z,11Z,14Z,17Z)

C29H39NO4 (465.2879)


   
   

ST 27:6;O2;Gly

ST 27:6;O2;Gly

C29H39NO4 (465.2879)


   

2-hydroxy-n-{1-[2-(2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}-3-methylpentanimidic acid

2-hydroxy-n-{1-[2-(2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}-3-methylpentanimidic acid

C24H39N3O6 (465.2839)


   

(3s,3ar,4s,6s,6ar,10r,14r)-3-benzyl-1,6,14-trihydroxy-4,10-dimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,11h,12h,13h,14h,15h,16h-cyclotrideca[d]isoindol-17-one

(3s,3ar,4s,6s,6ar,10r,14r)-3-benzyl-1,6,14-trihydroxy-4,10-dimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,11h,12h,13h,14h,15h,16h-cyclotrideca[d]isoindol-17-one

C29H39NO4 (465.2879)


   

7,8,19-trihydroxy-2,10-dimethyl-17-(octa-2,4-dien-1-yl)-16-azatetracyclo[12.6.0.0⁴,⁹.0¹⁶,²⁰]icosa-2,5,10,12-tetraen-15-one

7,8,19-trihydroxy-2,10-dimethyl-17-(octa-2,4-dien-1-yl)-16-azatetracyclo[12.6.0.0⁴,⁹.0¹⁶,²⁰]icosa-2,5,10,12-tetraen-15-one

C29H39NO4 (465.2879)


   

2-hydroxy-n-{1-[2-(2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}-n,3-dimethylbutanamide

2-hydroxy-n-{1-[2-(2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}-n,3-dimethylbutanamide

C24H39N3O6 (465.2839)


   

(2s)-2-hydroxy-n-[(2s)-1-[(2s)-2-[(2s)-2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-n,3-dimethylbutanamide

(2s)-2-hydroxy-n-[(2s)-1-[(2s)-2-[(2s)-2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-n,3-dimethylbutanamide

C24H39N3O6 (465.2839)


   

(2r)-2-[(2s,5r,6r)-6-[(3e,5e)-6-[(3as,4r,5r,7ar)-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid

(2r)-2-[(2s,5r,6r)-6-[(3e,5e)-6-[(3as,4r,5r,7ar)-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid

C29H39NO4 (465.2879)


   

(2s,3s)-2-hydroxy-n-[(2s)-1-[(2s)-2-[(2s)-2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3-methylpentanimidic acid

(2s,3s)-2-hydroxy-n-[(2s)-1-[(2s)-2-[(2s)-2-isopropyl-3-methoxy-5-oxo-2h-pyrrole-1-carbonyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-3-methylpentanimidic acid

C24H39N3O6 (465.2839)


   

(2r)-2-[(5s,6r)-5-methyl-6-[(3e,5e)-6-[(4s,5r)-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]oxan-2-yl]propanoic acid

(2r)-2-[(5s,6r)-5-methyl-6-[(3e,5e)-6-[(4s,5r)-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]oxan-2-yl]propanoic acid

C29H39NO4 (465.2879)


   

(3z,5e,7e,9e,11r,12s,13z,15e,17e,19e,21e,24s)-3-methoxy-5,11,17,21,24-pentamethyl-1-azacyclotetracosa-1,3,5,7,9,13,15,17,19,21-decaene-2,11,12-triol

(3z,5e,7e,9e,11r,12s,13z,15e,17e,19e,21e,24s)-3-methoxy-5,11,17,21,24-pentamethyl-1-azacyclotetracosa-1,3,5,7,9,13,15,17,19,21-decaene-2,11,12-triol

C29H39NO4 (465.2879)


   

(2r)-2-[(2r,5s,6r)-6-[(3e,5e)-6-[(3ar,4s,5r,7as)-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid

(2r)-2-[(2r,5s,6r)-6-[(3e,5e)-6-[(3ar,4s,5r,7as)-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid

C29H39NO4 (465.2879)


   

2-(5-methyl-6-{6-[4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl}oxan-2-yl)propanoic acid

2-(5-methyl-6-{6-[4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl}oxan-2-yl)propanoic acid

C29H39NO4 (465.2879)


   

2-amino-n-[4-amino-3-({3-amino-6-[(ethylamino)methyl]oxan-2-yl}oxy)-2-hydroxy-6-methoxycyclohexyl]-n-methylacetamide; carbonic acid

2-amino-n-[4-amino-3-({3-amino-6-[(ethylamino)methyl]oxan-2-yl}oxy)-2-hydroxy-6-methoxycyclohexyl]-n-methylacetamide; carbonic acid

C19H39N5O8 (465.2798)


   

(1s,2e,4r,7r,8s,9s,10e,12z,14s,17r,19s,20r)-7,8,19-trihydroxy-2,10-dimethyl-17-[(2e,4e)-octa-2,4-dien-1-yl]-16-azatetracyclo[12.6.0.0⁴,⁹.0¹⁶,²⁰]icosa-2,5,10,12-tetraen-15-one

(1s,2e,4r,7r,8s,9s,10e,12z,14s,17r,19s,20r)-7,8,19-trihydroxy-2,10-dimethyl-17-[(2e,4e)-octa-2,4-dien-1-yl]-16-azatetracyclo[12.6.0.0⁴,⁹.0¹⁶,²⁰]icosa-2,5,10,12-tetraen-15-one

C29H39NO4 (465.2879)